Artiva Biotherapeutics Taps Drug Development Veteran Diego Miralles as President and R&D Chief
Event summary
- Diego Miralles, M.D., appointed President and Head of R&D at Artiva Biotherapeutics, effective May 19, 2026.
- Miralles received an inducement grant of 232,500 stock options and 77,500 RSUs, vesting over four years.
- Miralles brings 20+ years of experience, including roles at Vividion, Laronde, and Johnson & Johnson.
- Artiva plans to initiate a Phase 3 trial for AlloNK in refractory rheumatoid arthritis in 2026.
- Miralles has served on Artiva’s Board of Directors since May 2024.
The big picture
Artiva Biotherapeutics is bolstering its leadership team with the appointment of Diego Miralles, a seasoned biotech executive with a proven track record in drug development and commercialization. This move comes as Artiva prepares to advance its lead candidate, AlloNK, through pivotal clinical trials, aiming to address a significant unmet need in the treatment of refractory rheumatoid arthritis and other autoimmune diseases. The strategic hiring underscores Artiva's focus on scaling its operations and positioning itself as a key player in the cell therapy space.
What we're watching
- Clinical Development
- Whether Artiva can successfully execute its Phase 3 trial for AlloNK in refractory rheumatoid arthritis and meet its 2029 BLA submission target.
- Leadership Impact
- How Diego Miralles' strategic and scientific judgment will shape Artiva's long-term R&D strategy and organizational growth.
- Market Positioning
- The pace at which Artiva can differentiate AlloNK in the competitive landscape of autoimmune disease treatments.
Related topics